Department of Gastroenterology, Centro Hospitalar Vila Nova de Gaia Espinho, Portugal.
Acta Gastroenterol Belg. 2021 Jan-Mar;84(1):87-90. doi: 10.51821/84.1.884.
Hepatic encephalopathy (HE) is a leading cause of hospitalization and morbimortality in advanced cirrhosis with limited therapeutic options available. Given the paramount role of gut microbiota in HE, and the efficacy of fecal microbiota transplantation (FMT) in other diseases, this review intends to summarize the evidence supporting the safety, efficacy and future perspectives of FMT in HE. Current evidence, despite being scarce, points towards FMT being a safe, effective and tolerable procedure in HE. Some unanswered questions remain about the optimal dose, the administration route, the long term effects and the selection of the optimal donor. Future trials, some of which are already underway, will provide us additional evidence and hopefully the necessary answers.
肝性脑病(HE)是肝硬化晚期导致住院和病死率的主要原因,目前治疗选择有限。鉴于肠道微生物群在 HE 中的重要作用,以及粪便微生物群移植(FMT)在其他疾病中的疗效,本综述旨在总结支持 FMT 在 HE 中的安全性、疗效和未来前景的证据。尽管目前的证据有限,但仍表明 FMT 是一种安全、有效且可耐受的 HE 治疗方法。关于最佳剂量、给药途径、长期效果和最佳供体选择等问题仍存在一些未解决的问题。一些已经在进行中的未来试验将为我们提供更多的证据,并希望能提供必要的答案。